MOLN vs PLUR

Molecular Partners AG vs Pluri Inc. — Valuation Comparison 2026

MOLN

Biological Products, (No Diagnostic Substances)
Molecular Partners AG
Quality
4.7
out of 10
Value Trap
26
LOW
Price
$4.00
Last close
Models
8/13
Active
VS

PLUR

Biological Products, (No Diagnostic Substances)
Pluri Inc.
Quality
5.6
out of 10
Value Trap
29
LOW
Price
$2.35
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType MOLN Fair ValueMOLN Upside PLUR Fair ValuePLUR Upside
Bayesian DCF Intrinsic $1.13 -71.8% $0.28 -88.1%
Earnings Power Value Intrinsic $0.82 -75.6%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.69 -57.9% $3.95 +68.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MOLN vs PLUR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MOLN vs PLUR — Which Stock Is More Undervalued?

PLUR scores higher with a 5.6/10 quality rating vs MOLN's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Molecular Partners AG (MOLN) and Pluri Inc. (PLUR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MOLN currently trades at $4.00 with a QOC of 4.7/10, while PLUR trades at $2.35 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).